The Ministry of Health and Prevention (MoHAP) has attended the signing ceremony of an agreement between Globalpharma, a wholly owned subsidiary of Dubai Investments, and GlaxoSmithKline, one of the world's leading research-based pharmaceutical and healthcare companies.
Lauding the agreement inked between the two sides, the Ministry stressed that it encourages foreign pharmaceutical companies to move some of their production lines to the UAE and take advantage of the country’s state-of-the-art infrastructure and modern systems that are tailored to facilitate investments in the pharmaceutical sector, and motivate international companies to strengthen their regional presence and produce innovative medicines in the UAE.
MoHAP added that it will spare no effort to ensure a stable and smooth supply of medicines in order to support the efficiency of the national pharmaceutical system.
The signing ceremony was attended by H.E. Dr. Amin Hussein Al Amiri, Assistant Undersecretary for the Health Regulation Sector, MoHAP, Patrick Moody, British Ambassador to the UAE, Gizem Akalin, GSK's Vice President and General Manager for the Gulf region, Mohammed Saeed Al Raqbani, General Manager of Dubai Investments Industries (DII) and General Manager of Globalpharma, and Basem Al Barahmeh, the General Manager of Globalpharma.
H.E. Dr. Amin Hussein Al Amiri stressed that the Ministry will spare no effort to establish a strategy that supports the efficiency of the UAE’s pharmaceutical system by expanding partnerships with factories and international companies. He added that MoHAP looks forward to enhancing the pharmaceutical manufacturing base and encouraging more companies to transfer their manufacturing operations to the country.
"The partnership between the UAE’s GlaxoSmithKline and the UK’s Globalpharma will not only enhance the sustainability of the pharmaceutical sector in the UAE, but will also help effectively meet the needs of all patients," Al Amiri said.
For his part, Patrick Moody said: "The partnership between GlaxoSmithKline and Globalpharma highlights the importance of the growing collaboration between the UK and the UAE in the field of life sciences, which reflects positively on patients. It also represents an additional milestone in the UAE's progress towards achieving its aspirations of developing a world-class hub for health care, life sciences, and biopharmaceutical industries."